Cargando…
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study()
While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower pr...
Autores principales: | de Renzis, Benoit, Mansat-De Mas, Veronique, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Cabrespine, Aurélie, Azgui, Zahia, Ades, Lionel, Kiladjian, Jean-Jacques, Fenaux, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850389/ https://www.ncbi.nlm.nih.gov/pubmed/24371784 http://dx.doi.org/10.1016/j.lrr.2013.06.003 |
Ejemplares similares
-
Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?
por: Kouroupi, E, et al.
Publicado: (2012) -
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2(V617F) myeloproliferative neoplasms
por: Courdy, Charly, et al.
Publicado: (2023) -
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019) -
Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018) -
JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
por: Dagher, Tracy, et al.
Publicado: (2020)